- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Obsidian Therapeutics, Inc. Common Stock(OBX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for OBX
11/13/2026: OBX (1-star) is currently NOT-A-BUY. Pass it for now.
Obsidian Therapeutics is a clinical-stage biotechnology company focused on developing engineered tumor-infiltrating lymphocyte cell therapies for solid tumors. Its main strength lies in its proprietary cytoDRiVE platform, which provides a unique method to regulate protein function in cancer treatment. The company’s primary investment story is the successful advancement of its lead candidate, Amsoki-cel, through clinical trials. Key risks include the inherent uncertainty of clinical development, intense competition from established biopharma firms, and the lack of current commercial revenue. This stock is best suited for growth-oriented investors with a high risk tolerance who are interested in monitoring upcoming clinical milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential through clinical breakthroughs but lacks current revenue or profitability. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find interest during clinical data milestones, though the stock is subject to high volatility. |
| Value investor | Weak fit | The absence of revenue and earnings makes this unsuitable for traditional value-based investment strategies. |
| Dividend investor | Weak fit | The company is a clinical-stage entity that does not pay dividends. |
| Low-risk investor | Weak fit | Extreme volatility and clinical development risk make this unsuitable for conservative, low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechs often experience wild price swings based on trial results and regulatory news. |
| Valuation risk | High | Without revenue, valuation is speculative and highly sensitive to management projections. |
| Competition risk (Immunotherapy) | Medium / high | Numerous well-capitalized firms compete in the TIL and cell therapy space. |
| Business quality | Medium | The company has proprietary technology but lacks the infrastructure and scale of established industry incumbents. |
| Dividend income | Low / none | Investors should expect zero income as capital is entirely dedicated to R&D. |
| Execution risk | High | Success depends entirely on the company's ability to successfully navigate complex Phase 1/2 and registration trials. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 775.87M USD | Price to earnings Ratio - | 1Y Target Price 39 |
Price to earnings Ratio - | 1Y Target Price 39 | ||
Volume (30-day avg) 480.7K shares | Beta 3.06 | 52 Weeks Range 9.60 - 49.97 | Updated Date 11/14/2026 |
52 Weeks Range 9.60 - 49.97 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.63 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Insufficient Data
The stock demonstrates a Insufficient Data price path pattern.

Insufficient Data
The stock price exhibits a Insufficient Data stability pattern.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Biotechnology R&D | Clinical trial development of Amsoki-cel and use of the cytoDRiVE platform. | The company currently makes no money; all cash comes from investors to fund research to create future medical products. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 720.73M | Price to Sales(TTM) - |
Enterprise Value 720.73M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 61.77M | Shares Floating 47.51M |
Shares Outstanding 61.77M | Shares Floating 47.51M | ||
Percent Insiders 1.13 | Percent Institutions 56.09 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

